MKP-1 as a target for pharmacological manipulations in PC12 cell survival

Neurochem Int. 2001 Jul;39(1):25-32. doi: 10.1016/s0197-0186(01)00004-3.

Abstract

Dual specificity mitogen activated protein kinase phosphatase-1 (MKP-1) inactivates extracellular signal-regulated kinase (ERK), p38 and/or c-jun N-terminal protein kinase (JNK) by dephosphorylation via a negative feed-back loop. The aim of the present study was to assess the role of expression of MKP-1 and phosphorylation status of mitogen-activated protein kinases (MAPKs) in promoting cell survival in PC12 cells. We used FK506 and three different monoperoxovanadium complexes (mpVs) as pharmacological tools for manipulation of MKP-1 expression. Peroxovanadium compounds, known to be insulinomimetic agents and protein tyrosine phosphatase inhibitors, are cytotoxic to the cells, they activate JNK and down-regulate MPK-1. On the other hand, FK 506 has transient effect on ERK activation. However, when the agents are used in combination, ERK phosphorylation is prolonged and intensified, MKP-1 expression is increased, and cell survival is enhanced. The concomitant alterations observed in intensities and duration of phospho-ERKs and phospho-JNKs signals suggest that monoperoxovanadium complexes in combination with FK 506 enhance survival of PC12 cells by an induction of MKP-1 expression.

MeSH terms

  • Animals
  • Cell Cycle Proteins*
  • Cell Survival*
  • Dual Specificity Phosphatase 1
  • Enzyme Activation
  • Immediate-Early Proteins / metabolism*
  • PC12 Cells
  • Phosphoprotein Phosphatases*
  • Phosphorylation
  • Protein Phosphatase 1
  • Protein Tyrosine Phosphatases / metabolism*
  • Rats
  • Tacrolimus / pharmacology
  • Vanadium Compounds / pharmacology

Substances

  • Cell Cycle Proteins
  • Immediate-Early Proteins
  • Vanadium Compounds
  • Phosphoprotein Phosphatases
  • Protein Phosphatase 1
  • Dual Specificity Phosphatase 1
  • Dusp1 protein, rat
  • Protein Tyrosine Phosphatases
  • Tacrolimus